Q32 Bio kerää 200 miljoonaa dollaria osakeannilla
Biotechnology company Q32 Bio announced it has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $200 million. The proceeds will fund working capital and clinical development.
Q32 Bio Inc., a clinical-stage biotechnology company, announced on July 14, 2026, the pricing of a public offering projected to raise around $200 million. The offering includes common stock and pre-funded warrants. The company intends to use the net proceeds for general working capital, research, clinical development, and commercialization efforts.
The offering consists of approximately 6 million shares of common stock and nearly 5 million pre-funded warrants, sold at prices of $18.25 and $18.2499 respectively. Underwriters have been granted an option to purchase additional shares. The transaction is expected to close around July 16, 2026. Funds raised will support the advancement of bempikibart, a potential therapy for alopecia areata and other autoimmune diseases, into future clinical trials.
Q32 Bio is developing therapies targeting autoimmune and inflammatory conditions. Bempikibart, an antibody targeting the IL-7Rα pathway, is currently in Phase 2 trials for alopecia areata. The company aims to re-balance the immune system with its therapeutic candidates. The financing provides capital to advance its pipeline.
Morgan Stanley, Jefferies, and Cantor Fitzgerald are acting as joint book-running managers, with Oppenheimer & Co. also serving as a book-running manager. H.C. Wainwright & Co. is the lead manager. The offering was made under a previously filed shelf registration statement with the U.S. Securities and Exchange Commission.